Recovery and half-life of factor VIII

被引：0
|
作者：
Koc, Basak [1 ,2 ]
Zulfikar, Bulent [1 ,2 ,3 ]
Ozcan, Hanife
机构：
[1] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey
[2] Inst Oncol, Istanbul, Turkey
[3] Hemophilia Soc Turkey, Istanbul, Turkey
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 53
页数：2
相关论文
共 50 条
  • [21] RECOVERY AND HALF-LIFE OF HUMAN FACTOR-VIII CONCENTRATES IN THE HEMOPHILIAC DOG AND THE INTERACTION OF F-VIII-C AND F-VIII-AG
    MIYASHITA, C
    HELLSTERN, P
    RODEMER, B
    KIEHL, R
    WENZEL, E
    HAEMOSTASIS, 1986, 16 : 26 - 26
  • [22] von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo
    Tang, L.
    Leong, L.
    Sim, D.
    Ho, E.
    Gu, J. -M.
    Schneider, D.
    Feldman, R. I.
    Monteclaro, F.
    Jiang, H.
    Murphy, J. E.
    HAEMOPHILIA, 2013, 19 (04) : 539 - 545
  • [23] Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
    Berntorp, Erik
    Andersson, Nadine G.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2016, 42 (05) : 518 - 525
  • [24] Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A
    Mannucci, Pier Mannuccio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 303 - 309
  • [25] Clinical application of extended half-life factor VIII in children with severe haemophilia A
    Dettoraki, Athina
    Michalopoulou, Aikaterini
    Mazarakis, Michalis
    Saslis, Stefanos
    Stamati, Ioanna
    Kapsimali, Zoey
    Pergantou, Helen
    HAEMOPHILIA, 2022, 28 (04) : 619 - 624
  • [26] Extended half-life factor
    Smith, Lan-Lan
    LANCET HAEMATOLOGY, 2020, 7 (09): : E636 - E636
  • [27] SAFETY, TOLERANCE, HALF-LIFE AND RECOVERY OF FACTOR-VIII - C (MONOCLATE) PASTEURIZED (P) IN PERSONS WITH HEMOPHILIA-A
    LUSHER, JM
    SALZMAN, P
    SHURAFA, M
    COHEN, A
    SMITH, K
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 181 - 181
  • [28] Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
    Megias-Vericat, J. E.
    Bonanad Boix, S.
    Berrueco Moreno, R.
    Mingot-Castellano, M. E.
    Rodriguez Lopez, M.
    Canaro Hirnyk, M.
    Mateo Arranz, J.
    Calvo Villas, J. M.
    Haya Guaita, S.
    Mesegue Meda, M.
    Lopez Jaime, F.
    Albo-Lopez, C.
    Palomero-Massanet, A.
    Vilalta Seto, N.
    Larrode Lecinena, I
    Cid Haro, A. R.
    Poveda Andres, J. L.
    THROMBOSIS RESEARCH, 2022, 216 : 35 - 42
  • [29] CLINICAL APPLICATION OF EXTENDED HALF-LIFE PEGYLATED FACTOR VIII IN CHILDREN WITH SEVERE HAEMOPHILIA A
    Dettoraki, A.
    Michalopoulou, A.
    Mazarakis, M.
    Saslis, S.
    Stamati, I.
    Kapsimali, Z.
    Pergantou, H.
    HAEMOPHILIA, 2022, 28 : 44 - 45
  • [30] In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds
    Josset, Laurie
    Rezigue, Hamdi
    Nougier, Christophe
    Leuci, Alexandre
    Desage, Stephanie
    Lienhart, Anne
    Dargaud, Yesim
    HAEMOPHILIA, 2025, 31 (02) : 224 - 230
12345